• KSCN
  • KSPAD
  • KSND
  • Contact us
  • E-Submission
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Articles

Page Path

Review Article

Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis

Nam-Hee Kim, Min Oh Lee
Korean Journal of Clinical Neurophysiology 2015;17(1):1-16.
Published online: June 30, 2015
Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
Corresponding author:  Nam-Hee Kim, Tel: +82-31-961-7214 , Fax: +82-31-961-7212, 
Email: nheekim8@hanmail.net
Received: 12 December 2014   • Accepted: 29 May 2015
  • 2,707 Views
  • 27 Download
  • 0 Crossref
  • 0 Scopus
next

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by progressive death of motor neurons in the cortex, brainstem, and spinal cord. Until now, many treatment strategies have been tested in ALS, but so far only Riluzole has shown efficacy of slightly slowing disease progression. The pathophysiological mechanisms underlying ALS are multifactorial, with a complex interaction between genetic factors and molecular pathways. Other motor neuron disease such as spinal muscular atrophy (SMA) and spinobulbar muscular atrophy (SBMA) are also progressive neurodegenerative disease with loss of motor neuron as ALS. This common thread of motor neuron loss has provided a target for the development of therapies for these motor neuron diseases. A better understanding of these pathogenic mechanisms and the potential pathological relationship between the various cellular processes have suggested novel therapeutic approaches, including stem cell and genetics-based strategies, providing hope for feasible treatment of ALS.

TOP